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Background: Postnatal insulin-like growth factor-1 (IGF-1) replacement with
recombinant human (rh)IGF-1 and IGF binding protein-3 (rhIGF-1/rhIGFBP-3) is being
studied as a potential treatment to reduce comorbidities of prematurity. We have recently
reported on a phase II, multicenter, randomized, controlled trial comparing postnatal
rhIGF-1/rhIGFBP-3 replacement with standard of care (SOC) in extremely preterm
infants (NCT01096784). Maximum severity of retinopathy of prematurity was the primary
endpoint of the trial and presence of GMH-IVH/PHI one of the pre-specified secondary
endpoints. Infants therefore received serial cranial ultrasound scans (CUS) between birth
and term age. In this post-hoc analysis we present a detailed analysis of the CUS data
of this trial and evaluate the effect of postnatal rhIGF-1/rhIGFBP-3 replacement on the
incidence of different kinds of brain injury in extremely preterm infants.
Methods: This report is an exploratory post-hoc analysis of a phase II trial in which
infants <28 weeks gestational age were randomly allocated to rhIGF-1/rhIGFBP-3 or
SOC. Serial cranial ultrasounds were performed between birth and term-equivalent age.
Presence of germinal matrix hemorrhage and intraventricular hemorrhage (GMH-IVH),
periventricular hemorrhagic infarction (PHI), post-hemorrhagic ventricular dilatation, and
white matter injury (WMI) were scored by two independent masked readers.
Results: The analysis included 117 infants; 58 received rhIGF-1/rhIGFBP-3 and 59
received SOC. A trend toward less grade II–III GMH-IVH and PHI was observed in treated
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infants vs. SOC. A subanalysis of infants without evidence of GMH-IVH at study entry (n
= 104) showed reduced progression to GMH-IVH in treated infants (25.0% [13/52] vs.
40.4% [21/52]; not significant). No effects of rhIGF-1/rhIGFBP-3 on WMI were observed.
Conclusion: The potential protective effect of rhIGF-1/rhIGFBP-3 on the occurrence of
GMH-IVH/PHI appeared most pronounced in infants with no evidence of GMH-IVH at
treatment start.
Keywords: neonate, brain injury, cerebral hemorrhage, recombinant human IGF-1, extremely preterm
INTRODUCTION
Despite advances in neonatal care and the widespread use
of antenatal steroids, prematurity-related brain injuries
such as germinal matrix hemorrhage and intraventricular
hemorrhage (GMH-IVH), periventricular hemorrhagic
infarction (PHI), post-hemorrhagic ventricular dilatation
(PHVD), and white matter injury (WMI) remain
common in extremely preterm infants (1–3). These
events are highly related to short- and long-term adverse
neurodevelopmental outcomes (4–6). It is therefore important
to evaluate novel strategies to prevent brain injury in these
vulnerable infants.
Postnatal levels of insulin-like growth factor-1 (IGF-1) in
extremely premature infants are lower than intrauterine levels at
a corresponding gestational age (GA) (7). IGF-1 is a major fetal
growth factor involved in a number of processes that include
metabolism, growth, and differentiation (8). Postnatal IGF-1
replacement with a complex of recombinant human (rh)IGF-1
and IGF binding protein-3 (rhIGF-1/rhIGFBP-3) is being studied
as a potential treatment to reduce comorbidities associated
with premature birth. A phase II, multicenter, randomized,
controlled trial recently compared postnatal rhIGF-1/rhIGFBP-
3 replacement with standard of care (SOC) in extremely
preterm infants (NCT01096784) (9). The maximum severity of
retinopathy of prematurity was the primary endpoint of the
trial and presence of GMH-IVH detected by cranial ultrasound
scans (CUS) was a pre-specified secondary endpoint. Results
of that trial showed a trend toward reduction in IVH favoring
active treatment. The study was not powered for a reduction
in IVH and some study infants already had evidence of GMH-
IVH at study entry, which also may have influenced the
results. The reason that some study infants had evidence of
GMH-IVH at study entry is because the baseline scan was
read locally to allow enrollment decisions within the first
24 h after birth. The effect of postnatal IGF-1 replacement on
incidence of PHVD and WMI detected by CUS has not yet
been reported.
We conducted post-hoc analyses of data from that
trial to clarify the findings relative to GMH-IVH, and to
further evaluate the effect of postnatal rhIGF-1/rhIGFBP-3
replacement on the incidence of prematurity-related brain
injury (GMH-IVH, PHI, PHVD, and WMI), as assessed
by CUS.
METHODS
Study Design and Patient Population
Themethods, study design, and results from the primary analyses
of the phase II study were reported previously (9). In brief,
this was a multicenter, randomized, SOC concurrent control,
assessor-masked study of rhIGF-1/rhIGFBP-3 (mecasermin
rinfabate, 50µg/ml solution) in extremely preterm infants
(ClinicalTrials.gov, NCT01096784). Eligible infants had a GA
at birth ranging from 23 weeks + 0 days to 27 weeks + 6
days. Exclusion criteria included detectable gross malformation,
known or suspected chromosomal abnormality, clinically
significant neurological disease, GMH-IVH grade II or III, or
PHI (infants with grade I GMH-IVH were included). Infants in
the active treatment group received a standardized dosage of 250
µg/kg per day of rhIGF-1/rhIGFBP-3 via continuous intravenous
infusion in addition to SOC from ≤24 h of birth until a post-
menstrual age (PMA) of 29 weeks+ 6 days. Infants in the control
group received SOC based on their individual medical needs and
according to local protocols. The primary endpoint of the phase
II study was maximum severity of retinopathy of prematurity
(ROP). Secondary endpoints included IVH, time to discharge
from neonatal care, bronchopulmonary dysplasia, and growth
parameters (9). A post-hoc analysis was conducted to further
explore the phase II study findings relative to IVH.
Written informed consent was provided by all infants’
parents/guardians. The study was reviewed/approved by
all relevant institutional review boards/independent ethics
committees of all participating centers.
Detection and Assessment of Brain Injury
on CUS
As part of the phase II trial, CUS examinations were performed
to detect and assess cerebral hemorrhage at study entry (day
0); at postnatal days 3, 7, 14, and 21 (±1 day); and at PMA
of 40 weeks (± 4 days). As initially reported, a single reader
(masked to treatment) evaluated all ultrasound images for the
highest grade of GMH-IVH, according to Papile and Bowerman
methods (10, 11). No IVH and grade I IVH were grouped
together. As a post-hoc follow up, CUS was re-examined for
GMH-IVH and PHI for each scan by two independent readers,
who were masked to treatment allocation. In addition, CUS
images were analyzed for the presence of PHVD and WMI.
GMH-IVH was graded according to Volpe (12); PHI was graded
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TABLE 1 | Cranial ultrasound image grading systems.
GMH-IVH graded according to Volpe method (12)
Severity Description
Grade I GMH with no or minimal IVH (<10% of ventricular area on
parasagittal view)
Grade II IVH in 10–50% of ventricular area on parasagittal view
Grade III IVH in >50% of ventricular area on parasagittal view; usually
distends lateral ventricle
Grade IV
(IVH and PHI)
IVH compounded by hemorrhagic venous infarction in the
periventricular white matter
PHI graded according to Dudink method (13)
Localization Caudate vein infarct
Temporal vein infarct
Anterior terminal vein infarct
Complete terminal vein infarct
Severity Description
Limited PHI Only caudate vein or temporal vein affected; small anterior terminal
vein infarction
Extensive PHI Complete terminal vein infarction or combination of caudate vein,
temporal vein, anterior vein infarctions
PHVD graded according to Davies method (14)
Severity Description
0 Normal, AHW <3 mm
1 Mild, AHW 3 to <5 mm
2 Moderate AHW 5–10 mm
3 Severe AHW >10 mm
White matter injury
Schematic description
• Persistent periventricular hyperechogenicity, no cysts, no obvious
white matter loss (white matter loss was identified as ventricular
dilatation without hemorrhage)
• Persistent periventricular hyperechogenicity evolving into diffuse
white matter loss, but no cysts
• Persistent periventricular hyperechogenicity evolving into small
localized frontoparietal cystic lesions (limited cystic PVL)
• Persistent periventricular hyperechogenicity evolving into extensive
cystic lesions (extensive cystic PVL)
Scoringa Description
0 Persistent periventricular hyperechogenicity or punctate lesions
without overt white matter loss, no cysts
1 Persistent periventricular hyperechogenicity or extensive punctate
lesions evolving in a white matter loss without cysts
2 Limited cystic PVL
3 Extensive cystic PVL
Brain injury severity score
0 No brain abnormalities
(Continued)
TABLE 1 | Continued
1 GMH, periventricular hyperechogenicity without white or gray
matter loss, and mild-moderate cerebral injury
2 IVH II, mild PHVD, stroke of a perforating artery
3 IVH III, persistent moderate PHVD without shunt or Rickham
device, persistent periventricular hyperechogenicities with diffuse
white and/or gray matter loss at term cranial ultrasound
4 Limited PHI, limited PVL, PHVD with shunt or Rickham device,
anterior cerebral artery stroke, posterior cerebral artery stroke,
severe cerebellar injury
5 Unilateral extensive PHI, extensive cystic PVL, mild cerebral artery
stroke, severe global brain atrophyb
6 Bilateral extensive PHI
AHW, anterior horn width; GMH, germinal matrix hemorrhage; IVH, intraventricular
hemorrhage; PHI, periventricular hemorrhagic infarction; PHVD, post-hemorrhagic
ventricular dilatation; PVL, periventricular leukomalacia.
aGrade 0 and grade I persistent periventricular hyperechogenicity were combined for
presentation in Figure 1; grade II and grade III were combined for cystic PVL.
bSevere global brain atrophy defined as a combination of global loss of gray and white
matter, delayed cortical folding, and enlarged lateral ventricles and subarachnoid spaces.
by localization and extent of the lesion according to Dudink
(13). PHVD was measured by anterior horn width (AHW)
according to Davies, and graded as follows: normal, <3mm;
mild, AHW 3 to <5mm; moderate, AHW 5–10mm; severe,
AHW>10mm [(14);Table 1].WMIwas schematically described
according to Govaert and de Vries (15), with presentation as
persistent periventricular hyperechogenicity, white matter loss,
or cystic periventricular leukomalacia (PVL). White matter loss
was identified as ventricular dilatation without hemorrhage on
CUS. WMI was scored using a four-grade classification. A seven-
grade brain injury severity score was developed by one of
the authors (SH) for use in the current study (not previously
published). The brain injury severity score utilized a classification
system where each grade reflected a greater degree of brain injury
(Table 1). The brain injury severity score was recorded for each
infant at 40 weeks PMA. Information on surgical intervention in
infants with PHVD (e.g., shunt, Rickham device) was collected
prospectively. Any discrepancy between the two readers was
resolved by consensus agreement.
Statistical Analysis
The current study included post-hoc analysis of brain injury
severity distribution, and a further subanalysis on GMH-IVH
progression in those infants without hemorrhage on the baseline
CUS. The severity distribution for GMH-IVH analysis included
all eligible infants in the phase II study. The distribution of
GMH-IVH according to treatment group was determined from
the maximum-grade hemorrhage observed for each infant in the
study population after randomization. A consensus maximum
GMH-IVH grade for each infant was defined based on the
highest grade of GMH-IVH observed by joint masked reader
review of all scans performed for that infant between day 0
and PMA 40 weeks (even in the event that some scans were
missing). In the subanalysis, the preventative effect of treatment
with rhIGF-1/rhIGFBP-3 on GMH-IVH was assessed based on
the progression of cerebral hemorrhage during the study among
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FIGURE 1 | Flowchart of infants included in the phase II study (9), the post-hoc analysis, and the subanalysis. GMH-IVH, germinal matrix hemorrhage and
intraventricular hemorrhage; rhIGF-1, recombinant human insulin-like growth factor-1; rhIGFBP-3, recombinant human insulin-like growth factor binding protein-3.
(Continued)
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FIGURE 1 | aOne infant had a serious adverse event with fatal outcome, but the primary reason for discontinuation was withdrawal of consent. bAll infants
discontinued due to a serious adverse event with fatal outcome. cSeven of nine discontinuations were due to serious adverse events with fatal outcome. dFor the
distribution analysis (n = 117), each infant was classified based on the maximum grade of GMH-IVH observed between day 0 and week 40 during a joint masked
consensus review of all available scans for that infant; one infant receiving standard of care and three infants receiving rhIGF-1/rhIGFBP-3 died within 72 h of
randomization and did not have an assigned maximum grade. eThe progression analysis (n = 104) was based on a comparison of longitudinal scans with the baseline
grade 0 scan for each eligible infant; 17 infants were excluded for the progression analysis: grade 0→ missing (n = 3); grade I→ grade I (n = 4); grade I→ grade II
(n = 2); grade II→ grade II (n = 3); grade II→ grade IV (n = 1); grade III→ grade IV (n = 1); grade IV→ grade IV (n = 1); missing→ grade 0 (n = 1); missing→
grade III (n = 1). Reprinted from Ley et al. (9), Copyright 2019, with permission from Elsevier. https://www.sciencedirect.com/science/article/pii/S0022347618315403.
infants with no evidence of GMH-IVH or PHI (classified as grade
0 GMH-IVH) at study entry. Progression to GMH-IVH in infants
with no evidence of hemorrhage at baseline was analyzed based
on the highest grade identified at any subsequent scan after the
baseline scan. The final analysis in the current study included
two different subgroups; 117 infants were included in the post-
hoc analysis for brain injury, and 104 infants were included in the
GMH-IVH progression analysis.
The Fisher exact test was performed to test the significance
of the difference between the rhIGF-1/rhIGFBP-3 treatment and
SOC groups. A p≤ 0.05 was regarded as significant. The grade of
GMH-IVH (grades I–III) or PHI was summarized descriptively
by treatment group and GA strata. Weighted kappa statistics
were used to measure interrater agreement between the two
readers. No power calculations were performed for comparing
GMH-IVH in this post-hoc analysis, since it was a secondary
endpoint; the trial was only powered for the primary endpoint of
maximum severity of retinopathy of prematurity in the primary
phase II study.
RESULTS
Brain Injury Severity Distribution Analysis
(n = 117)
A total of 121 infants were enrolled in the original phase II
trial, and details of patient disposition among these infants
have been previously reported (9). In the current study, 117
infants were assigned a maximum grade of GMH-IVH and
were included in the analysis for presence of brain injury
(Figure 1). Four infants died within 72 h of randomization and
were not assigned a maximum grade. The cause of death was
respiratory failure in each circumstance; baseline CUS revealed
no evidence of hemorrhage. Fifty-eight of 117 infants received
rhIGF-1/rhIGFBP-3 and 59 received SOC. Thirty-two of 58
(55.2%) treated infants and 31 of 59 (52.5%) control infants were
born before 26 weeks GA (Table 2).
GMH-IVH or PHI
A smaller proportion of treated infants had grade II–III GMH-
IVH or PHI, compared with control infants; the differences
were not statistically significant (Figure 2). Across all GAs, a
higher frequency of grade II–III GMH-IVH or PHI was observed
among infants receiving SOC vs. rhIGF-1/rhIGFBP-3 (Figure 3).
Among infants <25 weeks GA, a smaller proportion of rhIGF-
1/rhIGFBP-3–treated infants had grade II–III GMH-IVH or PHI
compared with controls (15.0% [n = 3/20] vs. 36.4% [n = 8/22],
respectively; not statistically significant).
TABLE 2 | Demographic characteristics and maternal/perinatal histories of infants
included in the post-hoc analysis (n = 117).
Characteristic Standard of care rhIGF-1/rhIGFBP-3
(n = 59) (n = 58)
Sex, n (%)
Male 38 (64.4) 38 (65.5)
Female 21 (35.6) 20 (34.5)
GA group, n (%)
<26 weeks 31 (52.5) 32 (55.2)
≥26 weeks 28 (47.5) 26 (44.8)
GA (weeks)
Mean (SD) 25 (1) 26 (1)
Weight at birth (g)
Mean (SD) 803 (175) 782 (186)
Race, n (%)
Asian 5 (8.5) 4 (6.9)
Black or African American 9 (15.3) 4 (6.9)
White 41 (69.5) 47 (81.0)
Other 4 (6.8) 3 (5.2)
Mode of delivery, n (%)
Vaginal 27 (45.8) 24 (41.4)
Cesarean section 32 (54.2) 34 (58.6)
Maternal infections, n (%) 14 (23.7) 10 (17.2)
Clinical chorioamnionitis, n (%) 6 (10.2) 9 (15.5)
Maternal antibiotics, n (%) 38 (64.4) 29 (50.0)
Antenatal steroids, n (%) 59 (100) 58 (100.0)
Fertility therapy, n (%) 8 (13.6) 8 (13.8)
In vitro fertilization 6 (10.2) 8 (13.8)
Ovulation stimulation 2 (3.4) 0
Preterm labor, n (%) 52 (88.1) 47 (81.0)
Preterm premature rupture of 20 (33.9) 16 (27.6)
membranes, n (%)
Preeclampsia, n (%) 5 (8.5) 7 (12.1)
Apgar score at 5min
Median (range) 7.0 (2.0–10.0) 8.0 (1.0–10.0)
GA, gestational age; rhIGF-1, recombinant human insulin-like growth factor-1; rhIGFBP-3,
recombinant human insulin-like growth factor binding protein-3; SD, standard deviation.
PHVD and WMI
Overall, the proportion of infants with PHVD was lower among
treated infants vs. controls (not statistically significant; Figure 2).
Mild PHVD (AHW 3–5mm) occurred in 1.7% (n = 1/58) of
infants in the treated group and 15.3% (n = 9/59) in the SOC
group. Moderate PHVD (AHW 5–10mm) occurred in 8.6%
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FIGURE 2 | Distribution of brain abnormalities among extremely preterm infants receiving rhIGF-1/rhIGFBP-3 or standard of care.a GMH-IVH, germinal matrix
hemorrhage and intraventricular hemorrhage; PHI, periventricular hemorrhagic infarction; PHVD, post-hemorrhagic ventricular dilatation; PVL, periventricular
leukomalacia; rhIGF-1, recombinant human insulin-like growth factor-1; rhIGFBP-3, recombinant human insulin-like growth factor binding protein-3. aBased on the
maximum-grade hemorrhage for each infant observed in cranial ultrasound on study days 0, 3, 7, 14, and 21, and at 40 weeks post-menstrual age.
(n= 5/58) in the treated group and 6.8% (n = 4/59) in the
SOC group. Severe PHVD (AHW >10mm) was low in both the
treated and SOC groups: 3.4% (n = 2/58) vs. 1.7% (n = 1/59),
respectively (these findings were not statistically significant). A
smaller proportion of infants in the rhIGF-1/rhIGFBP-3 group
had periventricular hyperechogenicity than among controls:
15.5% (n = 9/58) vs. 22% (n = 13/59), respectively (not
statistically significant; Figure 2). The proportion of treated vs.
control infants with ventricular dilatation without hemorrhage
(mild and moderate) was equal (10.3% [n = 6/58] vs. 10.2% [n
= 6/59], respectively). No infants had severe dilatation without
hemorrhage. The proportion of treated vs. control infants with
cystic PVL (limited and extensive) was equal (3.4% [n= 2/58] vs.
3.4% [n= 2/59], respectively).
Brain Injury Score
Compared with control infants, a higher proportion of infants in
the rhIGF-1/rhIGFBP-3 group had a brain injury severity score
of 0 (53.4 % [n = 31/58] vs. 42.4% [n = 25/59], respectively;
Figure 4). The proportion of infants with a severity score≥3 was
slightly higher among treated infants (25.9% [n = 15/58]) than
control infants (22.0% [n = 13/59]). These differences were not
statistically significant.
Overall, findings from the brain injury severity distribution
analysis among 117 infants showed no significant effect on brain
injury among treated infants vs. infants receiving SOC.
Subanalysis on the Preventative Effect of
rhIGF-1/rhIGFBP-3 on GMH-IVH (n = 104)
Of the total phase II study population (n = 121), 107 infants
had no evidence of GMH-IVH on CUS at study entry (14
infants had evidence of GMH-IVH grade >0 or missing data
at study entry). Three infants had a baseline scan only and
were excluded from the subanalysis. One infant, excluded
from the distribution analysis due to lack of assignment of
maximum grade owing to poor quality of day 3 CUS, was
included in the progression analysis. A total of 104 infants
were, therefore, included in the subanalysis of GMH-IVH
progression (Figure 1). Of these infants with no GMH-IVH
at study entry, 70 remained hemorrhage free over the course
of the study (39 infants in the rhIGF-1/rhIGFBP-3 group;
31 in the SOC group), while 34 developed GMH-IVH (13
in the rhIGF-1/rhIGFBP-3 group; 21 in the SOC group;
Table 3).
Among infants in the SOC group whose mothers had
infections, a significantly higher proportion developed GMH-
IVH than remained GMH-IVH free (38.1% [n = 8/21] vs.
12.9% [n = 4/31], respectively; p = 0.05). The difference
in the proportion of treated infants with maternal infections
who developed hemorrhages or remained hemorrhage free
was not statistically significant. A higher frequency of clinical
chorioamnionitis and maternal antibiotic use was observed
among infants who developed IVH/PHI in both the SOC and
rhIGF-1/rhIGFBP-3 treatment groups, compared with infants
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FIGURE 3 | Distribution of GMH-IVH grade II–III or PHI among infants assigned a maximum grade (n = 117), by treatment group and gestational age. GA, gestational
age; GMH-IVH, germinal matrix hemorrhage and intraventricular hemorrhage; PHI, periventricular hemorrhagic infarction; rhIGF-1, recombinant human insulin-like
growth factor-1; rhIGFBP-3, recombinant human insulin-like growth factor binding protein-3.
who remained hemorrhage free (not statistically significant;
Table 3).
GMH-IVH Progression
Among 104 infants who had no evidence of GMH-IVH on CUS
at study entry, there was a trend toward less progression to GMH-
IVH grade I–III or PHI among treated infants compared with
SOC (25.0% [n = 13/52] vs. 40.4% [n = 21/52], respectively;
p= 0.14; percentage risk difference,−15.4%; confidence interval
[CI],−34.6 to 4.8%; Figure 5).
DISCUSSION
To our knowledge, this is the first multicenter, randomized,
controlled trial to evaluate the effect of postnatal rhIGF-
1/rhIGFBP-3 replacement on brain injury in extremely preterm
infants, as assessed by serial CUS. Among the full population
in the current study (n = 117), we observed a lower prevalence
of grade II–III GMH-IVH and PHI in infants receiving rhIGF-
1/rhIGFBP-3 vs. infants receiving SOC. The prevalence of grade
I GMH-IVH and WMI (cystic PVL and white matter loss) was
broadly comparable between groups.
Post-hoc analysis of the serial CUS imaging data from the
phase II trial (9) by two independent central readers revealed
that 12 infants (6 in the treatment group, 6 in the control
group) had pre-existing GMH-IVH before treatment with rhIGF-
1/rhIGFBP-3 commenced, which may have attenuated the
observed protective effect of rhIGF-1/rhIGFBP-3 replacement on
the occurrence of GMH-IVH. Therefore, we performed a further
exploratory post-hoc analysis, including a subcohort of infants
without pre-existing GMH-IVH (n = 104), in order to study the
potentially preventive effect of rhIGF-1/rhIGFBP-3 replacement.
In this subcohort, 25.0% in the treatment group vs. 40.4% in
the SOC group developed GMH-IVH or PHI. Although not
statistically significant, we believe that the potentially beneficial
effect of rhIGF-1/rhIGFBP-3 replacement in preventing GMH-
IVH is more pronounced in the post-hoc analysis than we
were able to demonstrate in the clinical trial. No power
calculations were performed for comparing GMH-IVH (the
study was powered for the retinopathy of prematurity endpoint
in the primary study only). Dose-response characteristics for
this potentially beneficial effect will be further explored in a
larger clinical trial that is currently underway (EudraCT number:
2018-001393-16). If the protective effect of rhIGF-1/rhIGFBP-
3 can be confirmed in a larger cohort of preterm infants, early
administration of the drug may be beneficial to reduce GMH-
IVH occurrence.
While severe GMH-IVH (grade III and PHI) is commonly
used as an outcome parameter in clinical trials, low-grade
GMH-IVH (i.e., grade I and II) is not always considered a
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FIGURE 4 | Brain injury severity score among infants assigned a maximum grade (n = 117), by treatment group. rhIGF-1 recombinant human insulin-like growth
factor-1, rhIGFBP-3 recombinant human insulin-like growth factor binding protein-3.
relevant neonatal morbidity. Indeed, it has become customary
to inform parents that an uncomplicated, limited GMH-
IVH has no relevance in relation to long-term outcomes.
However, recent data have associated low-grade hemorrhage
with neurodevelopmental impairment in preterm infants (16).
A meta-analysis by Mukerji et al. found an increased risk for
moderate to severe neurodevelopmental impairment at 18–24
months (adjusted odds ratio, 1.39; 95% CI, 1.09–1.77) in infants
with mild (grade I and/or II) periventricular/intraventricular
hemorrhage compared with infants without hemorrhage (17).
Even though the meta-analysis was based on a limited amount of
data, low-grade GMH-IVH might in the future need to be taken
into account when considering clinical outcome.
The exact neurobiological basis of the adverse effect of
uncomplicated low-grade GMH-IVH on neurodevelopmental
outcome still needs to be elucidated, but it is likely multifactorial,
and there are several pathogenetic mechanisms that have
been related to the observed brain injury after low-grade
GMH-IVH. The destruction of the germinal matrix itself may
result in a relevant loss of glial precursor cells, leading to
impaired myelination, and cortical development (18, 19). Low-
grade GMH-IVH can be followed by abnormal microstructural
alterations in periventricular and subcortical white matter (20).
Even limited amounts of intraventricular blood can further
trigger inflammation in adjacent white matter through activated
microglia, passage of red blood cells, and red blood cell
degradation; the resulting perilesional tissue injury may be
secondary to free radical release and the presence of free iron
(21–24). In this context, we believe it is important to include
low-grade GMH-IVH as an outcome variable, although careful
long-term neurodevelopmental follow up of larger cohorts is
needed to prove this assumption.
Infants who experience PHVD after GMH-IVH carry a higher
risk of adverse neurodevelopmental outcomes than infants
without PHVD (25–27). In our cohort, 13.8% of infants receiving
rhIGF-1/rhIGFBP-3 developed some degree of PHVD, compared
with 23.7% of infants receiving SOC. However, the difference
was mainly due to an increased incidence of mild PHVD in
the control group, which is in line with the finding of a higher
prevalence of low-grade GMH-IVH in the control group. The
incidence of severe PHVD (AHW >10mm) was low, and
comparable in both groups (2 infants in the treatment group vs.
1 infant in the control group). Therefore, the clinical relevance of
the observed difference in subtle cases of PHVD between groups
remains speculative.
WMI is common in preterm infants (28, 29). The cystic
form of WMI, also known as cystic PVL, is highly associated
with cerebral palsy (28, 30). It can be reliably detected by serial
CUS imaging (31). Today, due to advances in neonatal care, it
has become a rare disease (32). The incidence of cystic PVL
was 3.4% in each of the study groups (rhIGF-1/rhIGFBP-3 and
SOC) in the current study, which is comparable to data from
population-based cohorts (1, 3). The non-cystic form of WMI,
the more common type of WMI in preterm infants today, can
present on CUS as persisting periventricular hyperechogenicity.
The incidence of periventricular hyperechogenicity was 15.5% in
the treatment group vs. 22.0% in the SOC group in the current
study. Non-cystic WMI can lead to impaired brain growth and
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TABLE 3 | Demographics, characteristics, and maternal/perinatal histories of infants with no GMH-IVH at study entry who either remained hemorrhage free or developed
GMH-IVH after study entry (n = 104).
Characteristic Infants who remained GMH-IVH free (n = 70) Infants who developed GMH-IVH (n = 34)
Standard of care
(n = 31)
rhIGF-1/rhIGFBP-3
(n = 39)
Standard of care
(n = 21)
rhIGF-1/rhIGFBP-3
(n = 13)
Sex, n (%)
Male 18 (58.1) 26 (66.7) 16 (76.2) 8 (61.5)
Female 13 (41.9) 13 (33.3) 5 (23.8) 5 (38.5)
GA group, n (%)
<26 weeks 11 (35.5) 19 (48.7) 16 (76.2) 9 (69.2)
≥26 weeks 20 (64.5) 20 (51.3) 5 (23.8) 4 (30.8)
GA (weeks)
Mean (SD) 26 (1) 26 (1) 25 (1) 25 (1)
Weight at birth (g)
Mean (SD) 836 (182) 779 (173) 747 (145) 816 (221)
Race, n (%)
Asian 2 (6.5) 3 (7.7) 3 (14.3) 1 (7.7)
Black or African American 5 (16.1) 1 (2.6) 4 (19.0) 3 (23.1)
White 22 (71.0) 32 (82.1) 13 (61.9) 9 (69.2)
Other 2 (6.5) 3 (7.7) 1 (4.8) 0
Mode of delivery, n (%)
Vaginal 14 (45.2) 14 (35.9) 8 (38.1) 8 (61.5)
Cesarean section 17 (54.8) 25 (64.1) 13 (61.9) 5 (38.5)
Maternal infections, n (%) 4 (12.9) 5 (12.8) 8 (38.1) 4 (30.8)
Clinical chorioamnionitis, n (%) 2 (6.5) 3 (7.7) 2 (9.5) 4 (30.8)
Maternal antibiotics, n (%) 17 (54.8) 18 (46.2) 17 (81.0) 8 (61.5)
Antenatal steroids, n (%) 31 (100) 39 (100) 21 (100) 13 (100)
Fertility therapy, n (%) 7 (22.6) 4 (10.3) 1 (4.8) 3 (23.1)
In vitro fertilization 5 (16.1) 4 (10.3) 1 (4.8) 3 (23.1)
Ovulation stimulation 2 (6.5) 0 0 0
Preterm labor, n (%) 27 (87.1) 29 (74.4) 19 (90.5) 13 (100)
Premature rupture of membranes, n (%) 9 (29.0) 9 (23.1) 8 (38.1) 6 (46.2)
Preeclampsia, n (%) 2 (6.5) 6 (15.4) 2 (9.5) 0
Apgar score at 5min
Median (range) 7.0 (2.0–10.0) 8.0 (3.0–10.0) 7.0 (4.0–10.0) 6.0 (1.0–9.0)
GA, gestational age; GMH-IVH, germinal matrix hemorrhage and intraventricular hemorrhage; rhIGF-1, recombinant human insulin-like growth factor-1; rhIGFBP-3, recombinant human
insulin-like growth factor binding protein-3; SD, standard deviation.
development and brain atrophy. One of the sonographic signs
of impaired brain development or loss of gray and white matter
volume is ventricular dilatationwithout hemorrhage on the term-
age ultrasound. This finding on term-age CUS has been shown
to correlate to long-term outcomes (33, 34). The prevalence of
ventricular dilatation without hemorrhage was identical in both
groups in the current trial (rhIGF-1/rhIGFBP-3 10.3% vs. SOC
10.2%). Therefore, we could not find evidence of either adverse
or beneficial effects of rhIGF-1/rhIGFBP-3 replacement on cystic
or non-cystic WMI with serial CUS.
The present data suggest that postnatal replacement therapy
with rhIGF-1/rhIGFBP-3 may have a beneficial effect on causal
mechanisms involved in the development of pretermGMH-IVH.
The rupture of vessels leading to GMH-IVH has been attributed
to an increased vulnerability of the germinal matrix vasculature
to fluctuations in cerebral blood flow (35). The vasculature of the
germinal matrix is in a highly proliferative phase and exhibits
a paucity of pericytes and an immature basal lamina low in
fibronectin (35). Further, circulating IGF-1 deficiency has been
shown to compromise the structural integrity of the cerebral
vasculature, resulting in decreased cerebral capillary density and
impaired cerebral myogenic autoregulation in preclinical studies
(36–38). The relationship between decreased circulating levels
of IGF-I and structural or functional aspects of the immature
blood-brain barrier remain to be elucidated.
The strength of this study is the multicenter, randomized,
controlled study design. Centers in five European countries and
the United States participated in the trial, which underlines
the generalizability of our findings. Furthermore, CUS was
performed serially from birth to term age and analyzed
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FIGURE 5 | Progression of GMH-IVH among infants with no evidence of GMH-IVH on cranial ultrasound at study entry (n = 104).a GMH-IVH, germinal matrix
hemorrhage and intraventricular hemorrhage; PHI, periventricular hemorrhagic infarction; rhIGF-1, recombinant human insulin-like growth factor-1; rhIGFBP-3,
recombinant human insulin-like growth factor binding protein-3. aSeventeen infants were excluded for the progression analysis: grade 0→ missing (n = 3); grade I
→ grade I (n = 4); grade I→ grade II (n = 2); grade II→ grade II (n = 3); grade II→ grade IV (n = 1); grade III→ grade IV (n = 1); grade IV→ grade IV (n = 1);
missing→ grade 0 (n = 1); missing→ grade III (n = 1).
independently by two masked readers, increasing reliability in
detection of not only mild hemorrhage, but also cystic and
non-cystic forms of WMI as well as severe brain atrophy.
Limitations include the relatively small sample size in our
treated and SOC cohorts, which could be a possible explanation
as to why a number of our results did not reach significance.
The trial was powered for the primary endpoint: maximum
severity of retinopathy of prematurity. Presence of GMH-IVH
was one of the pre-specified secondary endpoints, but the
study was not powered for IVH reduction, nor for reduction
of the other types of prematurity-related brain injury. It is
therefore important that a larger clinical trial is underway that
is planning to enroll ∼600 infants (EudraCT number: 2018-
001393-16; NCT03253263). An additional consideration is that
CUS was performed using the anterior fontanel as an acoustic
window. Additional visualization of the posterior fossa via
mastoid fontanel would have improved detection of cerebellar
injury (39, 40) but was not part of the initial study protocol.
Another limitation is that brain injury was evaluated by CUS
only. Magnetic resonance imaging (MRI) as a complementary
imaging modality would have certainly increased the sensitivity
and accuracy of the detection of prematurity-related brain injury,
and would have allowed detailed segmentation of different brain
regions and volumetric studies, as well as quantification of white
matter changes. However, acquiring high quality MRI data in
a multicenter study setting can be challenging compared to
sequential CUS. The advantage of CUS is that it is a bedside tool
that is nearly universally available in neonatal intensive care units,
and allows frequent serial imaging with minimal disturbance of
the infants and thereby gives valuable information on the timing
and evolution of brain injury. This can be crucial especially in
intervention studies like ours where timing of brain injury in
relation to drug application is an important aspect.
CONCLUSIONS
In this first multicenter, randomized, controlled trial comparing
rhIGF-1/rhIGFBP-3 replacement therapy with standard
treatment in extremely preterm infants, a trend toward less
grade II–III GMH-IVH and PHI in the treatment group
was observed across GAs. The potential protective effect of
rhIGF-1/rhIGFBP-3 was most pronounced in infants with no
evidence of GMH-IVH at the start of treatment. No effects of
rhIGF-1/rhIGFBP-3 replacement on WMI were observed. These
results support further investigation of the potential beneficial
effects of rhIGF-1/rhIGFBP-3 replacement in a larger cohort of
extremely preterm infants.
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